



## Psoriasis: A Review

Avdhut Arun Awate<sup>1</sup>, Rajvardhan Balasaheb Kadam<sup>2</sup>, Pavitra Santosh Kharkande<sup>3</sup>, Pankaj. S. Kore<sup>4</sup>  
Research Scholar, Research Scholar, Research Scholar, Assistant Professor.  
Rajarambapu College of Pharmacy Kasegaon, Dist. Sangli, Maharashtra, India-415404

### ABSTRACT

Psoriasis is a habitual multisystem seditious disorder that affects 01-1.5 of the world population. The classic cutaneous incarnation of psoriasis is scaled erythematous pillars, definite or extensively allotted. Also, psoriasis could be companied with comorbidities like Psoriatic arthritis, metabolic pattern, diabetes, cardiovascular disorder, nephropathy and brain disorders. This re-examination would assist to more make out and manipulate psoriasis.

**KEYWORDS:** Psoriasis, Plaque, Ayurveda, Kushta, Treatment, Raktavarnata

### INTRODUCTION

Psoriasis is habitual systemic seditious disorder that affects about 0.1-1.5 of the population worldwide.<sup>[1]</sup> Proinflammatory cytokines corresponding as interleukin (IL- 23, IL- 17) & tumour necrosis procurator (TNF-  $\alpha$ ) plays a judgmental functions in the inauguration and conservation of Psoriasis.<sup>[2]</sup> around 36 of cases with psoriasis possess a family record of psoriasis, and numerous hereditary susceptibility have been associated. Psoriasis could be activated by colourful kinds of external and natural threat factors. Determination of psoriasis is basically produced upon clinical findings and a skin dissection is needed. Oral treatments include traditional agents similar as methotrexate, acitretin, cyclosporine, and the advanced small patch apremilast, which is a phosphodiesterase 4 asset.<sup>[3]</sup> even so, immunogenic substantiation challenges the conventional taxonomy of psoriasis and suggests the reclassification of psoriasis into their subtypes.<sup>[4]</sup> Sustained absolution is an top thing in the operation of psoriasis, specifically for temperate to harsh psoriasis. Particular systemic drug similar as biologics, couldn't just treat psoriatic lesions but also help or enhance systemic comorbidities.<sup>[4]</sup>



Fig.1: Psoriasis

## KEYPOINTS

Psoriasis is a habitual immune-mediated seditious skin disorder has multiple phenotypically distinct subtypes i.e. shrine, flexural, guttate, pustular or erythrodermic.

- Psoriasis has a major hereditary element with heritability estimated to be 60- 90.
- High impact and sensitive to treat psoriasis spots include crown, face, nails, triumphs, and soles.
- Recognition and operation of comorbidities (similar as psoriatic arthritis, cardiovascular and hepatic disorder) is necessary part of holistic care of individual with psoriasis.
- Treatment of psoriasis include:
  1. Topical therapeutics(vitamin- D analogue and corticosteroids)
  2. Phototherapy{ narrowband ultraviolet B radiation( NB- UVB) and psoralen and ultraviolet A radiation( PUVA)}
  3. popular systemic agents(methotrexate, ciclosporin and acitretin)
  4. Targeted biologics{tumour necrosis factor(TNF), interleukin(IL)- 17 and(IL)- 23 inhibitors}
  5. Oral small patch obstacles{dimethyl fumarate and apremilast}<sup>[5]</sup>

## PATHOGENESIS

Psoriasis is Hyperproliferative skin disorder with enlarged rate of epidermal development.<sup>[6]</sup> The pathogenesis of psoriasis is linked to colorful cellular medium and the role of T cells, antigen present in cells( APCs), Langerhans cell, macrophages, natural chore cells, and array of Th1- type cytokines, as well as some growth agents like vascular endothelial growth factor( VEGF), keratinocytes growth factor( KGF),etc. have been indicated to play a key in the pathogenesis of psoriasis.<sup>[7]</sup> Psoriasis is an immunologically intermediated disorder; the activation of T lymphocytes leads to inflammation in dermal factors and secondary to the seditious incidents there's also that epidermal hyperproliferation.




Fig.2: Pathogenesis of psoriasis

Various mechanisms are hypothesized to be involved in the pathogenesis of psoriasis:

- T cell function
- Part of dendritic closet
- Hyperproliferation of keratinocytes
- Angiogenesis
- Cytokine intercessors
- degraded apoptosis
- hereditary factors<sup>[8]</sup>

## ETIOLOGY

Psoriasis has impact distinguishing from 0.2 to 4.8. The correct etiology is unknown but is called as an autoimmune disorder intermediated by T- lymphocytes. There's an affiliation of HLA antigens seen in numerous psoriatic cases. Some medicines like chloroquine, lithium, beta- blockers, steroids, and NSAIDs can decline the psoriasis. Injury in the form of mechanic and chemical trauma induces the psoriasis. Commonly, summer improves psoriasis while winter irritate it. The different factors activating psoriasis are infections, cerebral stress, hypocalcaemia, alcohol, smoking, and rotundity.<sup>[9]</sup>

## TREATMENT

When there's no treatment accessible for psoriasis for temperate disorder topical mediums are used systemic agents for several disorder and phototherapy for temperate disorder there's no substantiation to support the persuasiveness of systematized and conventional medicines phototherapy or natural remedy for an acute guttate flare or acute guttate psoriasis of habitual psoriasis.

## TOPICAL AGENTS:

The most operative are topical corticosteroids medication when used persist for eight weeks; coal navigator and retinoids having restricted assets and may be not better than placebo.<sup>[10]</sup> Advanced advantages have been obeyed with veritably potent corticosteroids.

Paricalcitol is vitamin D analogues are superior to placebo. Vitamin D and corticosteroid synthesis are superior for treatment of shrine psoriasis. Binary remedy or corticosteroid monotherapy set up to be more efficient and reliable than topical in 2016 review. For a little term treatment corticosteroid monotherapy is also satisfactory.

There's increase in concurrence of psoriatic pillars due to moisturizer and ointment similar as mineral oil, petroleum jelly, calcipotriol and decubal. Emollients when coupled with phototherapy it shows too effective in clearing psoriatic pillars. Some emollients have no collision on psoriasis shrine concurrence, or they indeed drop the concurrence built up by phototherapy. To demote inflammation the treated creams and ointments referred direct to psoriatic pillars. A Cochrane review of 177 RCTs, still, showed that corticosteroids performed at least as well as vitamin D3 analogues, with standardized mean differences ranging from -0.89( 95% CI-1.06 to -0.72) to -1.56( 95% CI-1.87 to -1.26) for potent and veritably potent corticosteroids, independently.<sup>[11]</sup>




Fig.3- Schematic psoriasis treatment ladder

## DRUGS USED IN TREATMENT OF PSORIASIS:

### 1) USTEKINUMAB-

It's humanized monoclonal antibody directed against p40, a subunit of IL- 23 and IL- 12 and inhibits their signal transduction paths that typically promotes the isolation of naive T cells into Th1 and Th17 cells independently. The treatment is started with dosage 45 mg at weeks 0 and 4 and every 12 weeks later.<sup>[12]</sup>

2) GUSELKUMAB- It's a natural monoclonal IgG1 $\alpha$  antibody that individually binds to the p19 subunit of IL- 23 and inhibits its relation with the IL- 23 receptor. Recommended remedy of guselkumab is subcutaneous injection of 100 mg at week 0, week 4 and every 8 weeks later.<sup>[13]</sup>

3) SECUKINUMAB- This remedy is utilized for moderate- to-severe psoriasis. This is either efficient than etanercept. This is used in dosage of subcutaneous injection of 300mg/ dose once a week. Some of the side effects are headache, diarrhoea, and infrequently neutropenia. It's approved by FDA to serve grown-ups with moderate- to-severe plaque psoriasis.<sup>[14]</sup>

## AYURVEDA IN TREATMENT OF PSORIASIS:

Psoriasis is an autoimmune complaint where inheritable and environmental factors have a significant part.<sup>[15]</sup> also, cytokines, seditious waterfall, and keratinocytes play an important part in the pathogenesis of psoriasis.<sup>[16]</sup> Among different types of psoriasis, shrine psoriasis( psoriasis vulgaris) is the most common form of psoriasis where argentine-white scales with raised areas of crimsoned skin are known as Pillars.<sup>[17]</sup> Being an autoimmune complaint, it's relatively delicate to treat. Thus, the treatment principles of Jirnajwara chikitsa, Vatarakta chikitsa, Rasayana chikitsa, and Kushtha chikitsa have been enforced together.

In the present case, pitta, kapha, and rakta were the Doshas, and Rasadhātu, Raktadhātu, and Mamsadhātu were the Dushyas. Doshā- dushya samurcchana( pathological progress) was taken place due to the rotation of vitiated Doshas and their Sthanasamshraya( point of pathological changes) at Tvaka( skin) with the clinical donation of Vyadhilakshnanas( signs and symptoms of psoriasis). The treatment protocol was espoused for Samprapti bhedana( to offset the pathophysiology) where Pitta- kaphahara, Jirnajwarahara, Vataraktahara, and Rasayana along with Kushthaghna aushadhiyogas( drugs) were preferred. Also, the Agnidipana( enhancement of the natural fire), Ampachana, Rasaprasadana( enhancement in the quality of blood), and Raktaprasadana( sanctification of the blood) were achieved with the help of all the internal drugs. The input of Viruddha ahara( the unwholesome salutary practices) is one of the important causative factors in the etiopathogenesis of skin conditions.

The case should avoid Viruddha ahara for better treatment response, speedy recovery, and to forestall the rush in habitual skin affections. In present case, the case was following the redundant use of salty and sour food particulars, old adulation and curd, racy food, contemporaneous use of milk products and salty snacks, etc. The case was taking ultramodern specifics without sidestepping the causative factors as par Ayurveda. Thus, temporary relief had observed with a relapsing pattern during the allopathic treatment. Therefore, in the present case, the strict salutary authority (Pathya) has been advised as the mollifying intervention along with Ayurveda drugs.<sup>[18]</sup>




Fig.4- psoriasis and ayurveda



## IMPLICATIONS OF AYURVEDA IN PSORIASIS:

General examination: Body temperature (97.6 °F), palpitation (88/ min), and Blood Pressure (118/86) were within normal limit.

### • Systemic examination

In systemic examination, respiratory and cardiovascular system set up normal. The case was restless due to itching and flaming feeling over psoriatic lesions.

### • Asthavidha pariksha:

Nadi( palpitation) – Pittakaphaja; Mala( coprolite) – Sandra- picchila, bowel habit was regular; Mutra( urine) – Prakrita; Jivha( lingo) – Shveta- picchila, Sama( carpeted); Shabda – Prakrita; Sparsha( touch) – Ushna; Drika( vision) – Prakrita; Aakriti – Madhyam( medium erected).

### • Nidana panchaka:

Nidana – Viruddhahara sevana( contemporaneous usage of milk and salty snacks) and Raktadushtikar Ahara- vihara( inordinate use of salty food, sour food like pickles, curd and sitting a lengthy time in immediate sunlight); Samprapti – Dosha – Pitta, Kapha and Rakta; Dushya – Rasadhatu, Raktadhatu and Mamsadhatu; Agni – Mandagni; Aam – Jatharagni and Dhatvagni janya; Strotasa – Rasavaha, Raktavaha and Mamsavaha; Adhithana – Twaka; Rogamarga – Bahya; Vyadhi Swabhava – Chirakari( habitual); Sadhyasadhyata – Kricchrasadhyata( tough to handle); Poorva roopa – Abhyantara daha( emotion of warmness), Kandu( itching), Mukhapaka( mouth ulcers) and Mandagni( anorexia); Roopa Jwara( sickness), Trishna( thirst), Daha( burning feeling), Kandu, Tvakavaivarnyata( in current case, skin with an adjustable shade of red color and the face covered with large argentine scales.), Balahani( generalized faintness); Upashaya – Bahya shita sparsha and Abhyanga( enhancement on watery cold sponging and oil usage); Anupashaya – Ushna sparsha( increased symptoms on work in hot and sticky ambience).

### • Diagnostic assessment:

All routine blood trials were within a routine range. The case wasn't fit for tissue dissection due to unaffordable expenditure. Thus, grounded on clinical presentation, dispensation of the skin damage, and positive Auspitz sign, the case determination was verified as shrine psoriasis. The Physician Global Assessment (PGA) is another simplified dimension tool that rates the inflexibility of psoriasis at a single point in time.<sup>[19]</sup>

### • Remedial interventions:

All oral and topical ultramodern medicaments stopped. In this case, the involvement of pitta and kapha dosha caught on by observing the clinical donation similar as Daha(burning feeling), Kandu( itching), Raktavarnata( reddishness), and the nature of skin lesions. Stained pitta and kapha dosha set up involved in the pathological progress. The details of the internal and external specifics specified have been mentioned in following table.

Tableno.1:Chart of internal and external medications with dose, adjuvant, and duration

| Sr. No. | Formulation   | Dose, frequency and time   | Adjuvant                | Duration <sup>a</sup> |
|---------|---|--|-------------------------|-----------------------|
| 1.      | <i>Patolakaturohinyadi kashaya</i> (Herbal decoction) | 20 mL of kashaya, twice daily on an empty stomach  | 50 mL of lukewarm water | 6 Month               |
| 2.      | <i>Mahatiktaka ghrita</i> (Capsule of medicated ghee) | 2 gm (4 capsules), once daily on an empty stomach at early morning   | Warm water              | 6 Month               |
| 3.      | <i>Gandhaka rasayana</i> (Tablet)                     | 250 mg (2 tablets) twice daily, after breakfast  | Water                   | 6 Month               |
| 4.      | <i>Khadirarishta</i> (Herbal fermented liquid)        | 20 mL of arishta, twice daily after meal   | 50 mL of normal water   | 6 Month               |
| 5.      | Winsoria oil (Herbal coconut base oil)                | Twice a day, Topical application   | –                       | 1 Year                |
| 6.      | Strict dietary plan                                   | Restricted use of salt, sour food items, curd, old butter, milk and sweet products, meat and fish, overeating etc. | –                       | 2 Years               |

## REFERENCE

1. Griffiths, C.E.M., Armstrong, A.W., Gudjonsson, J.E. and Barker, J.N.W.N.2021. Psoriasis. *Lancet* (London, England), [online] 397(10281): 1301–1315. doi:[https://doi.org/10.1016/S0140-6736\(20\)32549-6](https://doi.org/10.1016/S0140-6736(20)32549-6).
2. Nestle, F.O., Kaplan, D.H. and Barker, J. 2009. Psoriasis. *The New England journal of medicine*, [online] 361(5): 496–509. doi:<https://doi.org/10.1056/NEJMra0804595>.
3. Armstrong, A.W. and Read, C. 2020. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. *JAMA*, 323(19): 1945. doi:<https://doi.org/10.1001/jama.2020.4006>.
4. Yan, B.-X., Chen, X.-Y., Ye, L.-R., Chen, J.-Q., Zheng, M. and Man, X.-Y. 2021. Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. *Frontiers in Medicine*, [online] 8: 649408. doi:<https://doi.org/10.3389/fmed.2021.649408>.
5. Raharja A, Mahil SK, Barker JN.2021. Psoriasis: a brief overview. *Clin Med (Lond)*.21(3):170-173. doi: 10.7861/clinmed.2021-0257. PMID: 34001566; PMCID: PMC8140694.
6. Kumar, D., Rajguru, J., Maya, D., Suri, P., Bhardwaj, S. and Patel, N.2020. Update on psoriasis: A review. *Journal of Family Medicine and Primary Care*, 9(1): 20. doi:[https://doi.org/10.4103/jfmpe.jfmpe\\_689\\_19](https://doi.org/10.4103/jfmpe.jfmpe_689_19).
7. Das RP, Jain AK, Ramesh V.2009. Current concepts in the pathogenesis of psoriasis. *Indian J Dermatol*.54(1):7-12. doi: 10.4103/0019-5154.48977. PMID: 20049260; PMCID: PMC2800878.
8. Mehlis, SL & Gordon, KB 2003, 'The immunology of psoriasis and biologic immunotherapy', *Journal of the American Academy of Dermatology*, vol. 49(2) A:44-50.
9. Nair, P.A. and Badri, T. 2020. Psoriasis. [online] PubMed. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK448194/>.
10. Samarasekera, E.J., Sawyer, L., Wonderling, D., Tucker, R. and Smith, C.H. 2013. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. *British Journal of Dermatology*, 168(5): 954–967. doi:<https://doi.org/10.1111/bjd.12276>.
11. Mason AR, Mason J, Cork M, Dooley G, Edwards G. 2009. Topical treatments for chronic plaque psoriasis. *Cochrane Database Syst Rev*.(2):CD005028. doi: 10.1002/14651858.CD005028.pub2. Update in: *Cochrane Database Syst Rev*. 2013;3:CD005028. PMID: 19370616.
12. Gottlieb, A. and Narang, K. 2013. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. *Therapeutic Advances in Musculoskeletal Disease*, 5(5): 277–285. doi:<https://doi.org/10.1177/1759720x13501021>.
13. Nogueira, M. and Torres, T. 2019. Guselkumab for the treatment of psoriasis – evidence to date. *Drugs in Context*, 8: 1–11. doi:<https://doi.org/10.7573/dic.212594>.
14. Frieder, J., Kivelevitch, D. and Menter, A. 2018. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. *Therapeutic Advances in Chronic Disease*, [online] 9(1): 5–21. doi:<https://doi.org/10.1177/2040622317738910>.
15. Reali, E. and Brembilla, N.C. 2019. Editorial: Immunology of Psoriatic Disease. *Frontiers in Immunology*, 10. doi:<https://doi.org/10.3389/fimmu.2019.00657>.
16. Rendon, A. and Schäkel, K. 2019. Psoriasis Pathogenesis and Treatment. *International Journal of Molecular Sciences*, [online] 20(6): 1475. doi:<https://doi.org/10.3390/ijms20061475>.
17. Nille, G.C. and Chaudhary, A.K. 2021. Potential implications of Ayurveda in Psoriasis: A clinical case study. *Journal of Ayurveda and Integrative Medicine*, 12(1): 172–177. doi:<https://doi.org/10.1016/j.jaim.2020.11.009>.
18. Baliwag, J., Barnes, D.H. and Johnston, A. 2015. Cytokines in psoriasis. *Cytokine*, [online] 73(2): 342–350. doi:<https://doi.org/10.1016/j.cyto.2014.12.014>.
19. Kimmel GW, Lebwohl M.2018. Psoriasis: Overview and Diagnosis. *Evidence-Based Psoriasis*.1–16. doi: 10.1007/978-3-319-90107-7\_1. PMCID: PMC7122924.